NASDAQ:QTRX - Quanterix Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$22.96 -0.36 (-1.54 %)
(As of 02/21/2019 02:37 PM ET)
Previous Close$23.32
Today's Range$22.82 - $23.42
52-Week Range$13.00 - $23.50
Volume19,769 shs
Average Volume52,154 shs
Market Capitalization$509.71 million
P/E Ratio-2.77
Dividend YieldN/A
Beta1.37
Quanterix Corporation, a life sciences company, develops and markets ultra-sensitive digital immunoassay platform that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific. It develops Simoa HD-1 Analyzer, a sensitive protein detection platform, which analyzes approximately six biomarkers per test; and Quanterix SR-X, which utilizes the same technology and assay kit as the Simoa HD-1 Analyzer. The company's products include kits, such as beads, capture and detector reagents, enzyme reagents, and enzyme substrates to run tests; and consumables, such as proprietary Simoa disks, cuvettes, and disposable tips. In addition, it offers contract research services, including sample testing, homebrew assay development, and custom development services. The company primarily operates in the areas of neurology, oncology, cardiology, infectious diseases, and inflammation. It sell its products for the life science research sector primarily to laboratories associated with academic and governmental research institutions, as well as pharmaceutical, biotechnology, and contract research companies through a direct sales force, support organizations, and distributors or sales agents. Quanterix Corporation has collaboration agreements with DestiNA Genomics to focus on the development of a nucleic acid assay for direct detection and quantification of the liver toxicity biomarker microRNA-122; and OncoGenesis Corp to develop a protein biomarker diagnostic test for cervical health using its Simoa Planar Technology. The company was formerly known as Digital Genomics, Inc. and changed its name to Quanterix Corporation in August 2007. Quanterix Corporation was incorporated in 2007 and is headquartered in Lexington, Massachusetts.

Receive QTRX News and Ratings via Email

Sign-up to receive the latest news and ratings for QTRX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Analytical instruments
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:QTRX
CUSIPN/A
Phone617-301-9400

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$22.87 million
Book Value$3.02 per share

Profitability

Net Income$-27,010,000.00

Miscellaneous

Employees126
Market Cap$509.71 million
OptionableNot Optionable

Quanterix (NASDAQ:QTRX) Frequently Asked Questions

What is Quanterix's stock symbol?

Quanterix trades on the NASDAQ under the ticker symbol "QTRX."

When is Quanterix's next earnings date?

Quanterix is scheduled to release their next quarterly earnings announcement on Monday, March 18th 2019. View Earnings Estimates for Quanterix.

What price target have analysts set for QTRX?

2 equities research analysts have issued 1 year price targets for Quanterix's stock. Their forecasts range from $26.00 to $27.00. On average, they anticipate Quanterix's stock price to reach $26.50 in the next twelve months. This suggests a possible upside of 15.3% from the stock's current price. View Analyst Price Targets for Quanterix.

What is the consensus analysts' recommendation for Quanterix?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Quanterix in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Quanterix.

What are Wall Street analysts saying about Quanterix stock?

Here are some recent quotes from research analysts about Quanterix stock:
  • 1. According to Zacks Investment Research, "Quanterix Corporation is a developer of tools in high definition diagnostics. The Company focuses on research and diagnostics for brain injuries, heart disease, cancer and other diseases with its technology. It offers Simoa consumables, which include Simoa Discs, Simoa Cuvettes, Simoa Sealing Oil, Simoa Buffers and Disposable Tips. The company services include Simoa Accelerator Lab and custom assay development services. Quanterix Corporation is based in LEXINGTON, United States. " (1/25/2019)
  • 2. Canaccord Genuity analysts commented, "We think investors should own QTRX as it targets growth across 4 phases: 1) expansion in the life sciences research, followed by possible entry into new markets in 2) companion diagnostics; 3) point-of-care diagnostics; and 4) precision health and wellness screening, a $38 billion TAM. We reiterate our BUY rating and $27 PT. Q3 beat. Q3 revenues of $10.6M (+85% Y/Y, +61% adj.) topped our $8.4M (+47%)/ Street’s $8.3M, and included a 1-time payment of $1.3M from its licensing termination with BioMérieux. Product revs of $6.0M (+82% Y/Y) beat our $5.0M, while service revs (ex the 1-timer) of $3.0M was light of our $3.4M. QTRX beat us on consumables (+100% Y/Y beat our +70%) and instruments (+58% Y/Y beat our +30%). ~46% were in line with our 46.5%E. OPEX of $13.3M was above our $10.5ME. Net loss of ($7.7M) exceeded our ($6.9ME)." (11/7/2018)

Has Quanterix been receiving favorable news coverage?

News stories about QTRX stock have trended somewhat positive on Thursday, according to InfoTrie Sentiment. InfoTrie identifies negative and positive media coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Quanterix earned a news sentiment score of 0.9 on InfoTrie's scale. They also gave headlines about the company a news buzz of 9.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the company's share price in the next few days.

Who are some of Quanterix's key competitors?

What other stocks do shareholders of Quanterix own?

Who are Quanterix's key executives?

Quanterix's management team includes the folowing people:
  • Mr. E. Kevin Hrusovsky, Chairman, Pres & CEO (Age 58)
  • Dr. David R. Walt, Co-Founder, Chairman of Scientific Advisory Board & Director (Age 66)
  • Mr. Joseph S. Driscoll, Chief Financial Officer (Age 54)
  • Dr. David C. Duffy Ph.D., Sr. VP of R&D and CTO (Age 48)
  • Mr. Paul M. Meister M.B.A., Director (Age 66)

When did Quanterix IPO?

(QTRX) raised $50 million in an IPO on Thursday, December 7th 2017. The company issued 3,300,000 shares at a price of $14.00-$16.00 per share. J.P. Morga and Leerink Partners acted as the underwriters for the IPO and BTIG and Evercore ISI were co-managers.

Who are Quanterix's major shareholders?

Quanterix's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Royce & Associates LP (3.27%), BlackRock Inc. (2.97%), Jennison Associates LLC (1.34%), Bellevue Group AG (1.29%), Diag Capital Management LP (1.01%) and Northern Trust Corp (0.44%). Company insiders that own Quanterix stock include David R Walt, E Kevin Hrusovsky, Ernest Orticerio, John M Connolly, Joseph Driscoll and Venture Fund Viii Overage Arch. View Institutional Ownership Trends for Quanterix.

Which institutional investors are selling Quanterix stock?

QTRX stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, Bellevue Group AG, Royce & Associates LP, Barclays PLC, Acadian Asset Management LLC, Northern Trust Corp and Citigroup Inc.. Company insiders that have sold Quanterix company stock in the last year include E Kevin Hrusovsky, Ernest Orticerio and Joseph Driscoll. View Insider Buying and Selling for Quanterix.

Which institutional investors are buying Quanterix stock?

QTRX stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., Diag Capital Management LP, Squarepoint Ops LLC, Geode Capital Management LLC, Brandywine Managers LLC, Rhumbline Advisers, Granite Investment Partners LLC and Macquarie Group Ltd.. Company insiders that have bought Quanterix stock in the last two years include David R Walt, E Kevin Hrusovsky, John M Connolly and Venture Fund Viii Overage Arch. View Insider Buying and Selling for Quanterix.

How do I buy shares of Quanterix?

Shares of QTRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Quanterix's stock price today?

One share of QTRX stock can currently be purchased for approximately $22.99.

How big of a company is Quanterix?

Quanterix has a market capitalization of $510.38 million and generates $22.87 million in revenue each year. The company earns $-27,010,000.00 in net income (profit) each year or ($8.30) on an earnings per share basis. Quanterix employs 126 workers across the globe.

What is Quanterix's official website?

The official website for Quanterix is http://www.quanterix.com.

How can I contact Quanterix?

Quanterix's mailing address is 113 HARTWELL AVENUE, LEXINGTON MA, 02421. The company can be reached via phone at 617-301-9400.


MarketBeat Community Rating for Quanterix (NASDAQ QTRX)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  144 (Vote Outperform)
Underperform Votes:  165 (Vote Underperform)
Total Votes:  309
MarketBeat's community ratings are surveys of what our community members think about Quanterix and other stocks. Vote "Outperform" if you believe QTRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe QTRX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/21/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel